MedPath

Nogapendekin alfa inbakicept

Generic Name
Nogapendekin alfa inbakicept
Clinical Trials
Related News

Study of the Safety of Therapeutic Treatment With an Immunomodulatory Agent (N-803) in Adults With COVID-19

Phase 1
Conditions
COVID-19
Interventions
Other: Saline
First Posted Date
2020-05-13
Last Posted Date
2021-08-24
Lead Sponsor
ImmunityBio, Inc.
Target Recruit Count
1
Registration Number
NCT04385849
Locations
🇺🇸

St. Francis, Lynwood, California, United States

Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection

Phase 1
Completed
Conditions
Head and Neck Cancer
Head and Neck Neoplasms
Interventions
Biological: TriAd vaccine
First Posted Date
2020-01-30
Last Posted Date
2025-04-23
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
21
Registration Number
NCT04247282
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.

First Posted Date
2018-08-27
Last Posted Date
2025-02-21
Lead Sponsor
ImmunityBio, Inc.
Registration Number
NCT03647423
Locations
🇺🇸

Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States

QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer

First Posted Date
2018-07-02
Last Posted Date
2025-02-21
Lead Sponsor
ImmunityBio, Inc.
Registration Number
NCT03574649
Locations
🇺🇸

Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States

QUILT-3.088: NANT Pancreatic Cancer Vaccine

First Posted Date
2018-06-20
Last Posted Date
2025-02-21
Lead Sponsor
ImmunityBio, Inc.
Registration Number
NCT03563144
Locations
🇺🇸

Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States

QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine

First Posted Date
2018-06-20
Last Posted Date
2024-12-11
Lead Sponsor
ImmunityBio, Inc.
Target Recruit Count
2
Registration Number
NCT03563157
Locations
🇺🇸

Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States

QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine

First Posted Date
2018-06-12
Last Posted Date
2025-02-21
Lead Sponsor
ImmunityBio, Inc.
Registration Number
NCT03554109
Locations
🇺🇸

Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States

Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)

Phase 1
Completed
Conditions
Prostate Cancer
Solid Tumor
Metastatic Prostate Cancer
Advanced Solid Tumor
Prostate Neoplasm
Interventions
First Posted Date
2018-04-11
Last Posted Date
2024-11-25
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
53
Registration Number
NCT03493945
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

QUILT-1.004: A Single Center, Open-label, Pharmacokinetic Study of Subcutaneous ALT-803

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2017-12-22
Last Posted Date
2025-03-24
Lead Sponsor
Altor BioScience
Target Recruit Count
20
Registration Number
NCT03381586
Locations
🇺🇸

Quotient Sciences, Miami, Florida, United States

QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy

First Posted Date
2017-11-01
Last Posted Date
2024-12-12
Lead Sponsor
ImmunityBio, Inc.
Target Recruit Count
6
Registration Number
NCT03329248
Locations
🇺🇸

Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy